EBS
Emergent·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EBS
Emergent Biosolutions Inc.
A company that develops vaccines and therapeutics against biological agents which are potential weapons
Biological Technology
--
11/15/2006
New York Stock Exchange
900
12-31
Common stock
300 Professional Drive
, Gaithersburg
, MD 20879
--
Emergent Biosolutions Inc., founded in May 1998 in Michigan, USA, was changed to Delaware Corporation in June 2004. The company has two operating divisions: Biodefense and Bioscience. The company is a global life sciences company focused on providing innovative preparedness and response solutions to unexpected, intentional and naturally occurring public health threats.
Earnings Call
Q1/2025
Estimate EPS0.7
Actual EPS0.71
Estimate Revenue218.50M
Actual Revenue222.20M
Emergent BioSolutions Q1 2025: Unpacking Contradictions in NARCAN Growth, Margins, and International Strategy
May 08,2025 07:31
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EBS has released its 2025 Q3 earnings. EPS was reported at 1.06, versus the expected -0.12, beating expectations. The chart below visualizes how EBS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EBS has released its 2025 Q3 earnings report, with revenue of 231.10M, reflecting a YoY change of -21.34%, and net profit of 51.20M, showing a YoY change of -55.40%. The Sankey diagram below clearly presents EBS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
